The interactive floor installation at Arts Mission Oak Cliff celebrates Dsgn For Us’ fifth anniversary.

The consensus price target hints at a 39.7% upside potential for Design Therapeutics (DSGN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in ...

Get the latest Design Therapeutics, Inc. (DSGN) stock news and headlines to help you in your trading and investing decisions.

On March 19, 2024, Design Therapeutics Inc (NASDAQ:DSGN) released its 8-K filing, outlining significant progress across its GeneTAC platform and announcing its financial results for the fourth ...

Design Therapeutics Inc (NASDAQ:DSGN) announces Q3 2023 financial results with a net loss of $15.8 million. DSGN's cash reserves of approximately $290 million expected to support operations ...

Yet, DSGN stock is still likely to lose value in 2023 and might even be delisted someday. Based in California, Design Therapeutics develops genomic medicines for genetic disorders.

Design Therapeutics, Inc. (DSGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Dsgn For Us volunteer Nick Denman of Austin, takes photos of their project, “YELLOW,” an interactive paper installation, at Arts Mission in Oak Cliff, Thursday, March 21, 2024.